Pacira BioSciences, Inc. — Director's Dealing 2017

Aug 18, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2017-08-15

Reporting Person: STACK DAVID M (Director, CEO and Chairman)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-15	Common Stock	M	28885	$1.61	Acquired	159164	Direct
2017-08-15	Common Stock	S	28885	$36.37	Disposed	130279	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-15	Stock Option (Right to Buy)	$1.61	M	28885	Disposed	2020-09-02	Common Stock (28885)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18596	Indirect
Common Stock	1208	Indirect

Footnotes

F1: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.90, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: Mr. Stack is the general partner of Stack Schroon Mohawk FLP. Mr. Stack and his wife are the owners of LCK Investment LLC.

F4: The option vested as to 50% of the option shares on February 2, 2011, 19,378 option shares vested on February 3, 2011, and the remaining option shares vested in successive monthly installments for the subsequent 19 months.